XHKG
1066
Market cap1.85bUSD
Oct 09, Last price
3.31HKD
1D
1.53%
1Q
0.61%
Jan 2017
-36.10%
IPO
1,791.43%
Name
Shandong Weigao Group Medical Polymer Co
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Weigao Group Medical Polymer Company Limited, established in 2000 and based in Weihai, People's Republic of China, is primarily engaged in the research, development, manufacturing, and distribution of disposable medical products within the PRC and for export. The company operates through several specialized divisions: Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and other related ventures. Its comprehensive product range includes a vast array of single-use clinical items such as vascular and non-vascular access devices (e.g., infusion sets, syringes, various puncture needles), along with specialized collection kits. It also provides solutions for wound care, encompassing sutures, dressings, and cleaning products, as well as support systems for nonvascular catheters used in extracorporeal procedures. In the critical area of blood management, Shandong Weigao supplies equipment for blood collection, storage, separation, and sterilization, in addition to prefilled and flush syringes, and devices for blood collection and glucose testing. Furthermore, its portfolio extends to anesthesia consumables for general, local, and auxiliary applications, intensive care unit (ICU) equipment, and surgical instruments designed for both open and minimally invasive operations. The company also produces orthopedic devices, interventional tools for treating tumors and vascular conditions, various implantation materials, artificial organs, and medical-grade packaging components like PVC granules, plastic bags, and carton boxes. Industrial automation equipment, parts, molds, and hemodialysis apparatus, spanning Type I, Type II, and Type III medical devices, are also part of their extensive offerings. Beyond its core manufacturing activities, the company diversifies into finance leasing and factoring, wholesale distribution of specific medical and surgical disposables, asset management, and offers enterprise consulting and management advisory services, alongside logistics and storage solutions. Its products are marketed under well-known brands such as Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing, serving a broad client base including hospitals, blood banks, other medical facilities, and independent distributors.
Key people
Yi Wang
Vice Chairman, Executive Director · since 2019
Xue Feng Wu
Chief Financial Officer · since 2017
Hong Feng Ju
Deputy General Manager · since 2018
Jian Bo Gong
Executive Director · since 2013
Jing Long
Chief Executive Officer, Executive Director · since 2018
Miu Ling Wong
Company Secretary
Hua Wei Zhang
Executive Chairman of the Board, Compliance Officer · since 2016
Shu Hua Zhou
Non-Executive Director
Independent Non-Executive Director · since 2009
Independent Non-Executive Director · since 2012
Headquarters & legal address
火炬高技术产业开发区威高路1号
威海, SD 264210
CN
威海, SD 264210
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||